Molecular diagnostics firm Seegene and Springer Nature have launched "Nature Awards MDx Impact Grants in partnership with Seegene," a new project for the development of diagnostic assays, as part of their ongoing strategic partnership.
The program aims to empower researchers to develop innovative diagnostic assays using Seegene's advanced multiplex polymerase chain reaction (PCR) technology, the partners said in a statement.
This global call for proposals builds on the success of the partnership's 2023 Open Innovation Program. The program drew 281 applications from 47 countries, with 26 submissions selected.
The new program invites researchers to directly submit product development ideas featuring qualitative PCR-based analysis targeting human infectious diseases.
Researchers who are selected will receive significant support, including research funding of up to $600,000 per project, as well as Seegene's provision of syndromic PCR assays, extraction assays, consumables, instruments, and relevant software necessary for their clinical research project.
The application deadline is December 2, 2024. The first evaluation will conclude in February 2025, followed by onsite evaluation and final deliberation.
Final awards will be announced in August 2025. Nature Awards will lead the submission and evaluation process, while Seegene will manage overall program planning and onsite evaluations.
For more information on the program, please visit the program website.